Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) Income towards Parent Company (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Income towards Parent Company data on record, last reported at -$319.2 million in Q1 2026.

  • On a quarterly basis, Income towards Parent Company fell 115.91% to -$319.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$975.3 million, a 89.53% decrease, with the full-year FY2025 number at -$804.0 million, down 74.94% from a year prior.
  • Income towards Parent Company reached -$319.2 million in Q1 2026 per PCVX's latest filing, down from -$247.8 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for PCVX hit a ceiling of -$39.1 million in Q1 2022 and a floor of -$319.2 million in Q1 2026.
  • A 5-year average of -$130.1 million and a median of -$111.9 million in 2024 define the central range for Income towards Parent Company.
  • Peak YoY movement for Income towards Parent Company: tumbled 168.73% in 2022, then grew 29.81% in 2024.
  • Tracing PCVX's Income towards Parent Company over 5 years: stood at -$79.9 million in 2022, then crashed by 124.05% to -$179.1 million in 2023, then increased by 29.81% to -$125.7 million in 2024, then tumbled by 97.14% to -$247.8 million in 2025, then decreased by 28.81% to -$319.2 million in 2026.
  • Business Quant data shows Income towards Parent Company for PCVX at -$319.2 million in Q1 2026, -$247.8 million in Q4 2025, and -$213.1 million in Q3 2025.